+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dapagliflozin"

Non-Insulin Therapies for Diabetes Market Report 2025 - Product Thumbnail Image

Non-Insulin Therapies for Diabetes Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
Metformin Market Report 2025 - Product Thumbnail Image

Metformin Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
Antidiabetics Market Report 2025 - Product Thumbnail Image

Antidiabetics Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
From
From
Type 2 Diabetes Market Report 2025 - Product Thumbnail Image

Type 2 Diabetes Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Type 2 Diabetes Pipeline Analysis Report - Product Thumbnail Image

Type 2 Diabetes Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
From
From
FARXIGA Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

FARXIGA Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • April 2024
  • 30 Pages
  • Global
From
From
From
From
From
From
From
From
Loading Indicator

Dapagliflozin is a drug used to treat endocrine and metabolic disorders. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, leading to increased excretion of glucose in the urine. This helps to reduce blood sugar levels in people with type 2 diabetes. Dapagliflozin is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes. Dapagliflozin is available in both tablet and oral solution form and is typically taken once daily. Common side effects include urinary tract infections, increased urination, and genital yeast infections. The Dapagliflozin market is highly competitive, with several major pharmaceutical companies offering the drug. These include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Novo Nordisk. Show Less Read more